Novartis Kisqali increases OS in HRHER2 advanced breast cancer in phase 3 trial

Novartis’ Kisqali increases OS in HR+/HER2- advanced breast cancer in phase 3 trial

03:10 EDT 4 Jun 2019 | Pharmaceutical Business Review

The Kisqali combination therapy, which was evaluated in both pre- and perimenopausal women in the late-stage trial called MONALEESA-7, delivered statistically significant overall survival (OS) results in comparison

More From BioPortfolio on "Novartis’ Kisqali increases OS in HR+/HER2- advanced breast cancer in phase 3 trial"